Journal
CELL HOST & MICROBE
Volume 29, Issue 11, Pages 1611-+Publisher
CELL PRESS
DOI: 10.1016/j.chom.2021.10.003
Keywords
-
Categories
Funding
- South African Medical Research Council
- South African Department of Science and Innovation (DSI) [96825, SHIPNCD 76756, DST/CON 0250/2012]
- Poliomyelitis Research Foundation [21/65]
- Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa) from the Wellcome Trust [207511/Z/17/Z, 222754]
- NIH NIAID
- SARS-CoV-2 Assessment of Viral Evolution program [75N9301900065]
- South African Research Chairs Initiative of DSI
- National Research Foundation (NRF) [98341]
- L'Oreal/UNESCO Women in Science South Africa Young Talents award
- EDCTP2 program of the European Union [TMA2017SF-1951-TB-SPEC, TMA2016SF-1535-CaTCH-22]
- SA-MRC
- MRC UK
- NRF
- NIHR Biomedical Research Funding to University College London Hospitals
Ask authors/readers for more resources
The study shows that vaccination with Ad26.COV2.S after infection can significantly enhance protection against COVID-19, especially against different virus variants. In addition, the vaccine also induces robust CD4 and CD8 T cell responses, regardless of prior infection.
The Johnson and Johnson Ad26.COV2.S single-dose vaccine represents an attractive option for coronavirus disease 2019 (COVID-19) vaccination in countries with limited resources. We examined the effect of prior infection with different SARS-CoV-2 variants on Ad26.COV2.S immunogenicity. We compared participants who were SARS-CoV-2 naive with those either infected with the ancestral D614G virus or infected in the second wave when Beta predominated. Prior infection significantly boosts spike-binding antibodies, antibody dependent cellular cytotoxicity, and neutralizing antibodies against D614G, Beta, and Delta; however, neutralization cross-reactivity varied by wave. Robust CD4 and CD8 T cell responses are induced after vaccination, regardless of prior infection. T cell recognition of variants is largely preserved, apart from some reduction in CD8 recognition of Delta. Thus, Ad26.COV2.S vaccination after infection could result in enhanced protection against COVID-19. The impact of the infecting variant on neutralization breadth after vaccination has implications for the design of second-generation vaccines based on variants of concern.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available